



S-11-09

1632

Express Mail No. ER 505 058 638 US

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: HARIRI Confirmation No.: 7788  
Serial No.: 10/004,942 Art Unit: 1632  
Filed: December 5, 2001 Examiner: Li, Qian Janice  
For: METHOD OF COLLECTING Attorney Docket No.: 9516-100-999  
PLACENTAL STEM CELLS (CAM:) (501872-999099)

## SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure provisions of 37 C.F.R. §1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the application.

1. Enclosures accompanying this Information Disclosure Statement are:
  - 1a.  A list of all patents, publications, applications, or other information submitted for consideration by the office.
  - 1b. A legible copy of:
    - Each U.S. patent application publication and U.S. and foreign patent;
    - Each publication or that portion which caused it to be listed on the PTO-1449;
    - For each cited pending U.S. application, the application specification including the claims, and any drawing of the application, or portion of the application which caused it to be listed on the PTO-1449 including any claims directed to that portion;
    - all other information or portion which caused it to be listed on the PTO-1449.
  - 1c.  An English language copy of search report(s) from a counterpart foreign application or PCT International Search Report.
  - 1d.  Explanations of relevancy (ATTACHMENT 1(d), hereto) or English language abstracts of the non-English language publications.
2.  This Information Disclosure Statement is filed under 37 C.F.R. §1.97(b):
  - Within three months of the filing date of a national application other than a continued prosecution application under §1.53(d);
  - Within three months of the date of entry of the national stage as set forth in §1.491 in an international application;

- Before the mailing of the first Office action on the merits;
- Before the mailing of a first Office action after the filing of a request for continued examination under §1.114.
3.  This Information Disclosure Statement is filed under 37 C.F.R. §1.97(c) after the period specified in 37 C.F.R. §1.97(b), but before the mailing date of any of a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311 or an action that otherwise closes prosecution in the application.

*(Check either Item 3a or 3b)*

- 3a.  The Certification Statement in Item 5 below is applicable. Accordingly, no fee is required.
- 3b.  The \$180.00 fee set forth in 37 C.F.R. §1.17(p) in accordance with 37 C.F.R. §1.97(c) is:
- enclosed
- to be charged to Jones Day Deposit Account No. 503013.

*(Item 3b to be checked if any reference known for more than 3 months)*

4.  This Information Disclosure Statement is filed under 37 C.F.R. §1.97(d) after the period specified in 37 C.F.R. §1.97(c), but on or before the date of payment of the issue fee.

The Certification Statement in Item 5 below is applicable.

The \$180.00 fee set forth in 37 C.F.R. §1.17(p) is:

- enclosed.
- to be charged to Jones Day Deposit Account No. 503013.

5.  Certification Statement (applicable if Item 3a or Item 4 is checked)

*(Check either Item 5a or 5b)*

- 5a.  In accordance with 37 C.F.R. §1.97(e)(1), it is certified that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.
- 5b.  Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart application, and the communication was not received by any individual designated in 37 C.F.R. §1.56(c) more than thirty days prior to the filing of this information disclosure statement.
- 5c.  Pursuant to 37 C.F.R. §1.704(d), each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart application, and the communication was not received by any individual designated in 37 C.F.R. §1.56(c) more than thirty days prior to the filing of this information disclosure statement.

6.  This application is a continuation application under 37 C.F.R. §1.60 or §1.53(b) or (d).

*(Check appropriate Items 6a, 6b and/or 6c)*

- 6a.  A Petition to Withdraw from issue under 37 C.F.R. §1.313(b)(5) is concurrently filed herewith.
- 6b.  Copies of publications listed on Form PTO-1449 from prior application Serial No. , filed on , of which this application claims priority under 35 U.S.C. §120, are not being submitted pursuant to 37 C.F.R. §1.98(d).
- 6c.  Copies of the publications listed on Form PTO-1449 were not previously cited in prior application Serial No. , filed on , and are provided herewith.
7.  This is a Supplemental Information Disclosure Statement.
- 7a.  This Supplemental Information Disclosure Statement under 37 C.F.R. §1.97(f) supplements the Information Disclosure Statement filed on . A bona fide attempt was made to comply with 37 C.F.R. §1.98, but inadvertent omissions were made. These omissions have been corrected herein. Accordingly, additional time is requested so that this Supplemental Information Disclosure Statement can be considered as if properly filed on .
8.  In accordance with 37 C.F.R. §1.98, a concise explanation of what is presently understood to be the relevance of each non-English language publication is:

*(Check Item 8a, 8b, or 8c)*

- 8a.  satisfied because all non-English language publications were cited on the enclosed English language copy of the PCT International Search Report or the search report from a counterpart foreign application indicating the degree of relevance found by the foreign office.
- 8b.  set forth in the application.
- 8c.  enclosed as an attachment hereto.
9.  The Commissioner is authorized to charge any additional fee required or credit any overpayment for this Information Disclosure Statement and/or Petition to Jones Day Deposit Account No. 503013.
10.  No admission is made that the information cited in this Statement is, or is considered to be, material to patentability nor a representation that a search has been made (other than a search report of a foreign counterpart application or PCT International Search Report if submitted herewith). 37 C.F.R. §§1.97(g) and (h).

Respectfully submitted,

*B. J. L. S. G. Reg. No. 49,020  
Anthony M. Insogna 35,203*  
Anthony M. Insogna (Reg. No.)  
JONES DAY  
222 East 41st Street  
New York, New York 10017  
(212) 326-3939

Date: May 10, 2004



**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

ATTY DOCKET NO.	APPLICATION NO
9516-100-999	10/004,942
APPLICANT	CONFIRMATION NO.
Hariri	7788

FILING DATE  
December 5, 2001

GROUP  
1632

**U.S. PATENT DOCUMENTS**


*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
A1	5,192,553	4/2/99	Boyse et al.			
A2	5,372,581	12/13/94	Anderson			
A3	5,415,665	5/16/95	Hessel et al.			
A4	5,635,387	6/3/97	Fei et al.			
A5	5,665,557	9/9/97	Murray et al.			
A6	5,670,351	9/23/97	Emerson et al.			
A7	5,827,735	10/27/98	Young et al.			
A8	5,874,301	2/23/99	Keller et al.			
A9	5,879,318	3/9/99	Van der Heiden et al.			
A10	5,905,041	5/18/99	Beug et al.			
A11	5,914,108	6/22/99	Tsukamoto et al.			
A12	5,914,268	6/22/99	Keller et al.			
A13	5,916,202	6/29/99	Haswqell			
A14	5,919,176	7/6/99	Kuypers et al.			
A15	5,993,429	11/30/99	Kuypers et al.			
A16	6,030,836	2/29/00	Thiede			
A17	6,110,739	8/29/00	Keller et al.			
A18	6,179,819	1/30/01	Haswel			
A19	6,190,368	2/20/01	Kuypers et al.			
A20	6,255,112	7/3/01	Thiede et al.			

**FOREIGN PATENT DOCUMENTS**

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES
B1	WO 00/17325	3/30/00	PCT			
B2	WO 00/73421	12/7/00	PCT			

**OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)**

C1	Contractor et al., "A comparison of the effects of different perfusion regimes on the structure of the isolated human placental lobule. Cell Tissue Res. 237:609-617 (1984)
C2	Hatzopoulos et al., "Isolation and characterization of endothelial progenitor cells from mouse embryos", Development 125:1457-1468 (1998)
C3	Moore et al., "A simple perfusion technique for isolation of maternal intervillous blood mononuclear cells from human placentae", J. Immunol. Methods 209:93-104 (1997)
C4	Shambrott et al., "Derivation of pluripotent stem cells from cultured human primordial germ cells", Proc. Natl. Acad. Sci. U S A. 95:13726-13731 (1998). Erratum in: Proc. Natl. Acad. Sci. U S A 96:1162 (1999)
C5	Thompson et al., "Embryonic stem cell lines derived from human blastocysts", Science 282:1145-1147 (1998); Erratum in: Science 282:1827 (1998)



C6	Turner et al., "A modified harvest technique for cord blood hematopoietic stem cells", Bone Marrow Transplant. <u>10</u> :89-91 (1992)
C7	Wang et al., "Enhanced recovery of hematopoietic progenitor and stem cells from cultivated postpartum human placenta", Blood <u>98</u> (11/1):183a, abstract no. 769 (2001)
C8	Ye et al., "Recovery of placental-derived adherent cells with mesenchymal stem cell characteristics", Blood <u>98</u> (11/1):147b, abstract no. 4260 (2001)

EXAMINER	DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.